ArticleMolecular oncology2025

MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-cell lung cancer.

Jie Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.